161 related articles for article (PubMed ID: 29691365)
1. Plasma inflammatory cytokines and survival of pancreatic cancer patients.
Babic A; Schnure N; Neupane NP; Zaman MM; Rifai N; Welch MW; Brais LK; Rubinson DA; Morales-Oyarvide V; Yuan C; Zhang S; Poole EM; Wolpin BM; Kulke MH; Barbie DA; Wong K; Fuchs CS; Ng K
Clin Transl Gastroenterol; 2018 Apr; 9(4):145. PubMed ID: 29691365
[TBL] [Abstract][Full Text] [Related]
2. Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer.
Rasmussen LS; Yilmaz MK; Falkmer UG; Poulsen LØ; Bøgsted M; Christensen HS; Bojesen SE; Jensen BV; Chen IM; Johansen AZ; Hansen CP; Hasselby JP; Holländer N; Nielsen SE; Andersen F; Bjerregaard JK; Pfeiffer P; Johansen JS
Eur J Cancer; 2021 Feb; 144():72-80. PubMed ID: 33341448
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory cytokines and angiogenic factors as potential biomarkers in South African pancreatic ductal adenocarcinoma patients: A preliminary report.
Yako YY; Brand M; Smith M; Kruger D
Pancreatology; 2017; 17(3):438-444. PubMed ID: 28377069
[TBL] [Abstract][Full Text] [Related]
4. A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma.
Xu J; Shi KQ; Chen BC; Huang ZP; Lu FY; Zhou MT
J Gastroenterol Hepatol; 2017 Jul; 32(7):1394-1402. PubMed ID: 27973703
[TBL] [Abstract][Full Text] [Related]
5. Prognosis Relevance of Serum Cytokines in Pancreatic Cancer.
Torres C; Linares A; Alejandre MJ; Palomino-Morales RJ; Caba O; Prados J; Aránega A; Delgado JR; Irigoyen A; Martínez-Galán J; Ortuño FM; Rojas I; Perales S
Biomed Res Int; 2015; 2015():518284. PubMed ID: 26346854
[TBL] [Abstract][Full Text] [Related]
6. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma.
Dima SO; Tanase C; Albulescu R; Herlea V; Chivu-Economescu M; Purnichescu-Purtan R; Dumitrascu T; Duda DG; Popescu I
Pancreas; 2012 Oct; 41(7):1001-7. PubMed ID: 22722257
[TBL] [Abstract][Full Text] [Related]
7. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer.
Rahbari NN; Schmidt T; Falk CS; Hinz U; Herber M; Bork U; Büchler MW; Weitz J; Koch M
BMC Cancer; 2011 Jul; 11():286. PubMed ID: 21729304
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy.
Kieler M; Unseld M; Wojta J; Kaider A; Bianconi D; Demyanets S; Prager GW
Med Oncol; 2018 Nov; 36(1):1. PubMed ID: 30426271
[TBL] [Abstract][Full Text] [Related]
9. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
10. Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort.
Grote VA; Kaaks R; Nieters A; Tjønneland A; Halkjær J; Overvad K; Skjelbo Nielsen MR; Boutron-Ruault MC; Clavel-Chapelon F; Racine A; Teucher B; Becker S; Pischon T; Boeing H; Trichopoulou A; Cassapa C; Stratigakou V; Palli D; Krogh V; Tumino R; Vineis P; Panico S; Rodríguez L; Duell EJ; Sánchez MJ; Dorronsoro M; Navarro C; Gurrea AB; Siersema PD; Peeters PH; Ye W; Sund M; Lindkvist B; Johansen D; Khaw KT; Wareham N; Allen NE; Travis RC; Fedirko V; Jenab M; Michaud DS; Chuang SC; Romaguera D; Bueno-de-Mesquita HB; Rohrmann S
Br J Cancer; 2012 May; 106(11):1866-74. PubMed ID: 22617158
[TBL] [Abstract][Full Text] [Related]
11. Serum JAK/STAT profile is related to the IL expression but not with the outcome in pancreatic adenocarcinoma patients.
Petrusel L; Ilies M; Leucuta D; Rusu I; Seicean A; Iuga C; Seicean R
Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):107-112. PubMed ID: 34933726
[TBL] [Abstract][Full Text] [Related]
12. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival.
Yuan C; Qian ZR; Babic A; Morales-Oyarvide V; Rubinson DA; Kraft P; Ng K; Bao Y; Giovannucci EL; Ogino S; Stampfer MJ; Gaziano JM; Sesso HD; Buring JE; Cochrane BB; Chlebowski RT; Snetselaar LG; Manson JE; Fuchs CS; Wolpin BM
J Clin Oncol; 2016 Aug; 34(24):2899-905. PubMed ID: 27325858
[TBL] [Abstract][Full Text] [Related]
13. Shorter Treatment-Naïve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma.
Antwi SO; Bamlet WR; Cawthon RM; Rabe KG; Druliner BR; Sicotte H; Jatoi A; Mahipal A; Boardman LA; Oberg AL; Petersen GM
Cancer Epidemiol Biomarkers Prev; 2021 Jan; 30(1):210-216. PubMed ID: 33187969
[TBL] [Abstract][Full Text] [Related]
14. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
15. Serum calcium level used as a prognostic predictor in patients with resectable pancreatic ductal adenocarcinoma.
Dong Q; Zhang Y; Yang XH; Jing W; Zheng LQ; Liu YP; Qu XJ; Li Z
Clin Res Hepatol Gastroenterol; 2014 Oct; 38(5):639-48. PubMed ID: 24630955
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern.
Kim HW; Lee JC; Paik KH; Kang J; Kim J; Hwang JH
Medicine (Baltimore); 2017 Feb; 96(5):e5926. PubMed ID: 28151872
[TBL] [Abstract][Full Text] [Related]
17. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer.
Ramsey ML; Talbert E; Ahn D; Bekaii-Saab T; Badi N; Bloomston PM; Conwell DL; Cruz-Monserrate Z; Dillhoff M; Farren MR; Hinton A; Krishna SG; Lesinski GB; Mace T; Manilchuk A; Noonan A; Pawlik TM; Rajasekera PV; Schmidt C; Guttridge D; Hart PA
Pancreatology; 2019 Jan; 19(1):80-87. PubMed ID: 30497874
[TBL] [Abstract][Full Text] [Related]
18. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
19. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients.
Szkandera J; Stotz M; Absenger G; Stojakovic T; Samonigg H; Kornprat P; Schaberl-Moser R; Alzoughbi W; Lackner C; Ress AL; Seggewies FS; Gerger A; Hoefler G; Pichler M
Br J Cancer; 2014 Jan; 110(1):183-8. PubMed ID: 24201751
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications and diagnostic usefulness of correlation between soluble major histocompatibility complex class I chain-related molecule a and protumorigenic cytokines in pancreatic ductal adenocarcinoma.
Chung HW; Jang S; Lim JB
Cancer; 2013 Jan; 119(1):233-44. PubMed ID: 22736451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
